Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer
Abstract
The purpose of the present work is to evaluate the use of HSV oncolytic vectors and their cytokine-containing derivatives as potential therapeutic modalities in treating prostate cancer. To this end, we have exploited the use of the transgenic TRAMP mouse, which recapitulates the developmental hallmarks of prostate cancer in humans. In last year's progress report, we made substantial strides in addressing all three specific aims. This year, we have added additional experiments to solidify this work and have subsequently submitted a manuscript entitled, Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses" to Cancer Research to be reviewed for publication (see attached manuscript in appendix). Furthermore, we have recently implemented a novel complementary approach using human prostate explants derived from cancer biopsies to further assess the efficacy of oncolytic HSV virotherapy. Our preliminary data shows that oncolytic HSV's specifically targets epithelial cells within the prostatic ducts and remarkably, leaves the surrounding stroma unaffected.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2007
- Accession Number
- ADA474667
Entities
People
- Brent J. Passer
Organizations
- Massachusetts General Hospital